Prostatype Genomics AB (FRA:PGO) Cash-to-Debt : 17.58 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Prostatype Genomics AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Prostatype Genomics AB's cash to debt ratio for the quarter that ended in Jun. 2023 was 17.58.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Prostatype Genomics AB could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Prostatype Genomics AB's Cash-to-Debt or its related term are showing as below:

FRA:PGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 0.86 Max: 16.05
Current: 0.23

During the past 5 years, Prostatype Genomics AB's highest Cash to Debt Ratio was 16.05. The lowest was 0.23. And the median was 0.86.

FRA:PGO's Cash-to-Debt is ranked worse than
77.19% of 228 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.285 vs FRA:PGO: 0.23

Prostatype Genomics AB Cash-to-Debt Historical Data

The historical data trend for Prostatype Genomics AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Prostatype Genomics AB Cash-to-Debt Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Cash-to-Debt

0.86

0.39

16.09

13.40

0.23

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											20.23	13.40	2.81	17.58	0.23

Competitive Comparison of Prostatype Genomics AB's Cash-to-Debt

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prostatype Genomics AB's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Cash-to-Debt falls into.

Prostatype Genomics AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Prostatype Genomics AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.24	/	(1.037	+	0.006)
	=	0.23

Prostatype Genomics AB's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.002	/	(0.034	+	0.023)
	=	17.58

Prostatype Genomics AB (FRA:PGO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Prostatype Genomics AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (FRA:PGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (FRA:PGO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PROGEN:Sweden

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (FRA:PGO) Headlines

No Headlines